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Naturally occurring peptides often possess macro-
cyclic and N-methylated backbone. These features
grant them structural rigidity, high affinity to targets,
proteolytic resistance, and occasionally membrane
permeability. Because such peptides are produced
by either nonribosomal peptide synthetases or
enzymatic posttranslational modifications, it is yet
a formidable challenge in degenerating sequence or
length and preparing libraries for screening bioactive
molecules. Here, we report a new means of synthe-
sizing a de novo library of ‘‘natural product-like’’
macrocyclic N-methyl-peptides using translation
machinery under the reprogrammed genetic code,
which is coupled with an in vitro display technique,
referred to as RaPID (random nonstandard peptides
integrated discovery) system. This system allows
for rapid selection of strong binders against an
arbitrarily chosen therapeutic target. Here, we have
demonstrated the selection of anti-E6AP macrocy-
clic N-methyl-peptides, one of which strongly in-
hibits polyubiqutination of proteins such as p53.
INTRODUCTION
Peptides discovered as natural products share structural
features that are not seen in ordinary polypeptides (proteins)
expressed by the translation apparatus. Such ‘‘nonstandard’’
peptides are often macrocyclized and N-methylated in the
backbone (Chatterjee et al., 2008); moreover, some of their
side chains are modified to noncanonical functional groups or
epimerized to D-configuration (Gru¨newald and Marahiel, 2006;
Kohli et al., 2002; Li and Roller, 2002). These features concede
critical biological and pharmacological properties, such as high
affinity to binding partners, proteolytic resistance, and mem-
brane permeability, and thus increase their specific potencies
in vivo (Biron et al., 2008; Doedens et al., 2010; Driggers et al.,
2008; Nestor, 2009; Sagan et al., 2004). Most of these peptides
are produced by nonribosomal peptide synthetases (Gru¨newald1562 Chemistry & Biology 18, 1562–1570, December 23, 2011 ª2011and Marahiel, 2006; Kohli et al., 2002; Li and Roller, 2002) or are
derived from ribosomally expressed peptides by enzymatic
posttranslational modifications (Chatterjee et al., 2005;McIntosh
et al., 2009; Oman and van der Donk, 2010). Despite the fact that
libraries of ‘‘natural product-like’’ nonstandard peptides could
be a very attractive source for drug discovery campaigns, the
mechanistic and functional complexities of their production
systems have been making it difficult for researchers to degen-
erate the sequences and lengths of nonstandard peptides and
build their de novo library. Therefore, we have not yet witnessed
a successful outcome of the generation of a highly complex
‘‘human-made’’ library and the discovery of novel peptide
sequences against therapeutic targets.
Here, we report a unique means of synthesizing a ‘‘natural
product-like’’ peptide library using a custom-made translation
apparatus under the reprogrammed genetic code. The peptides
in the library have the features of macrocyclic and N-methylated
backbone along with a D-amino acid involvement in the
sequences. Moreover, the library could be coupled with an
in vitro display, and thus over a trillion members of nonstandard
peptides can be rapidly screened against a chosen target. We
referred to this platform system as RaPID (random nonstandard
peptides integrated discovery) system. As a showcase of this
system, we have performed selection of anti-E6AP macrocyclic
N-methyl-peptides, and one of the abundant classes of selected
peptides exhibited an inhibitory activity against E6AP-catalyzed
polyubiquitination of target proteins, such as p53 and peroxire-
doxin 1. Thus, the present work demonstrates a proof-of-tech-
nology and potentials of the RaPID system for the discovery of
a novel class of nonstandard peptides against not only an E3
Ubquitin ligase but also previously nondruggable target families.RESULTS AND DISCUSSION
Design of a Nonstandard Peptide Library Used
in the RaPID System
The methodology of genetic code reprogramming, where
arbitrary codons are reassigned from proteinogenic amino acids
to nonproteinogenic amino acids, allows us to express
‘‘nonstandard’’ peptides using a translation apparatus (Forster
et al., 2003; Josephson et al., 2005; Ohta et al., 2007; Ohta
et al., 2008). To facilitate such a reprogramming, we haveElsevier Ltd All rights reserved
Figure 1. In Vitro Selection of Macrocyclic N-Methylated Peptides against E6AP HECT Domain by RaPID System
(A) The genetic code reprogrammed for this study. Four N-methyl-amino acids (MeF, MeS, MeA, and MeG) and chloroacetyl-D-tryptophan (ClAcDW) are shown in
red and blue, respectively.
(B) Overview of the RaPID system for the selection of macrocyclic N-methyl-peptides. Messenger RNA libraries containing random sequence domain, (NNU)8-15,
were transcribed from the corresponding cDNA library and were conjugated with an oligonucleotide bearing a 30-puromycin residue. The resulting mRNAs were
translated by FIT system in the presence of the appropriate aminoacyl-tRNAs prepared by flexizymes. Linear peptides displayed on the individual mRNAs were
spontaneously cyclized after translation, and the resulting macrocyclic peptides are displayed. The peptide libraries were then subjected to biotin-Avi-
(His)6-GB1-HECT immobilized on streptavidin magnetic beads (SAvB), and active species are isolated. Reverse transcription was performed after the selection in
the first round and before the selection from the second round. The cDNAs on active mRNA-peptide fusion were recovered and amplified by PCR.
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et al., 2011). This system involves a custom-made Escherichia
coli reconstituted cell-free translation system (Kung et al.,
1977; Shimizu et al., 2001), where arbitrary amino acids and
cognate aminoacyl-tRNA synthetases (ARSs) can be omitted
to make the corresponding codons vacant, to which nonprotei-
nogenic amino acids are assigned by supplementing the corre-
sponding aminoacyl-tRNAs prepared by the flexizyme (flexible
tRNA acylation ribozyme) technology (Murakami et al., 2006;
Ohuchi et al., 2007). In fact, by using a customized FIT system,
we were able to express macrocyclic N-methyl-peptides under
the genetic code reprogrammed with more than four kinds of
N-methyl-amino acids (Kawakami et al., 2008). To construct
highly diverse libraries of nonstandard peptides and to effec-
tively screen them for designated bioactivity, the FIT system
was further integrated with an in vitro display method, so-called
mRNA display (Nemoto et al., 1997; Roberts and Szostak, 1997).
By this integration, nonstandard peptides expressed by the FIT
system would be covalently ligated to the respective mRNAs
via puromycin, displaying nonstandard peptides for the desired
activity panning. We referred this mRNA display system inte-
grated with FIT system to as RaPID (random nonstandard
peptides integrated discovery) system.
In the present work, we assigned five nonproteinogenic amino
acids, N-(2-chloroacetyl)-D-tryptophan (ClAcDW), N-methylphe-
nylalanine (MeF), N-methylserine (MeS), N-methylglycine (MeG),
and N-methylalanine (MeA), to AUG, UUU, CUU, AUU,
and GCU codons by the addition of ClAcDW-tRNAfMetCAU,
MeF-tRNAAsn-E2GAA,
MeS-tRNAAsn-E2GAG,
MeG-tRNAAsn-E2GAU,
and MeA-tRNAAsn-E2GGC, respectively, prepared by the flexizyme
technology (Figure 1A). A mRNA library was constructed to
have NNU codon (N represents any of four bases, A, G, C,Chemistry & Biology 18, 1562–157and U) with the mixture of repeats from eight to 15, (NNU)8–15;
thereby, N-methyl-amino acids would randomly appear in this
region with the lengths of eight to 15 residues. In right down-
stream of the random region, UGC that assigns cysteine (Cys)
was installed. Because all expressed peptides should have a
ClAcDW at the N terminus assigned by AUG start codon, the
ClAc group would intramolecularly react with the sulfhydryl
group of the Cys residue assigned by UGC or potentially UGU
appeared in the random region, macrocyclizing their backbone
via a nonreducible thioether bond (Goto et al., 2008; Kawakami
et al., 2008). Following the UGC codon, three repeats of
(GGC)(AGC) encoding (Gly-Ser)3 followed by UAG stop codon
are embedded. The 30 common sequence would facilitate
the display of macrocyclic N-methyl-peptides on the respec-
tive mRNA molecules via the (Gly-Ser)3-puromycin linkage
(Figure 1B).
Three critical notes should be given for securing a high
quality of the macrocyclic N-methyl-peptide library: (1) In this
FIT system, the amino acids and their cognate ARSs, whose
codons were reprogrammed (F, L, I, and A), were omitted from
the translation components, minimizing the unwanted incor-
poration of these proteinogenic amino acids competing with
the N-methyl-amino acids. Similarly, those unassigned by NNU
codons (Q, K, E, and W) were omitted. Moreover, release
factor-1 (RF1) was withdrawn to aim at halting elongation at
UAG codon and thus increasing the efficiency of puromycin-
peptide fusion. (2) Because four of 16 codons assigned by
the NNU mRNA library encode N-methyl-amino acids, one
N-methyl-amino acid residue would appear in every four resi-
dues by chance. Our previous studies suggested the thioether
macrocyclization takes place cleanly in nearly quantitative
manner, regardless of the length and composition of peptide0, December 23, 2011 ª2011 Elsevier Ltd All rights reserved 1563
Figure 2. E6AP-Catalyzing Polyubiqutination of Target Proteins in E6-Independent and -Dependent Manners
In general, ubiquitin-activating enzyme E1 delivers an ubiquitin molecule (Ub) onto ubiquitin-conjugating enzyme E2 via a thioester linkage, and then Ub on E2 is
transferred to ubiquitin ligase E3 forming a conjugate, E3-Ub. E6AP HECT (homologous to E6-associated protein [E6AP] C-terminus) domain (PDB 1C4Z),
belonging to a member of E3 protein family, cooperatively catalyzes polyubiquitination on certain proteins, such as p53, with E6 (E6-dependent pathway) or
directly polyubiquitinates various target proteins (E6-indendent pathway).
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because no stop codon was encoded in the (NNU)8–15 random
region, the highly reliable macrocyclic N-methyl-peptide library
could be displayed by RaPID system. (3) The initial mRNA
library consists of greater than 6 3 1012 unique members. It
should be noted that the complexity of (NNU)8–15 mRNA library
should almost directly reflect to the peptide library complexity
because only Ser is redundant in the genetic triplets used.
Because the generally observed yield of mRNA-peptide fusion
in the FIT system was 30% or more of the total input of mRNA,
the diversity of the initial RaPID display library was estimated
to be 1012 or more.
RaPID Selection against E6AP HECT Domain
The ubiquitin-proteasome system regulates the degradation
of cellular proteins through enzyme cascade consisting of
ubiquitin-activating enzyme E1, ubiquitin-conjugating enzyme
E2, and ubiquitin (Ub) ligase E3 (Figure 2) (Hershko and Ciechan-
over, 1998; Pickart, 2001). Many families of E3 Ub ligases are
known and are responsible for specific conjugation of polyubi-
quitins (polyUbs) to designated proteins, directing them to
proteasome and thus triggering their proteolysis. Misregulation
of the proteolysis of certain proteins caused by malfunction of
E3 family ligases influences their downstream signal transduc-
tion processes, and therefore causes human disorders such as
cancer (Hoeller et al., 2006) and neurodegeneration (Layfield
et al., 2005; Rubinsztein, 2006). Thus, these E3 Ub ligases could
be attractive targets for new therapeutic intervention (Eldridge
and O’Brien, 2010; Hoeller and Dikic, 2009; Nalepa et al.,
2006). Homologous to E6AP C-terminus (HECT) domain belongs
to a family member of E3, and its N terminus domain cooperates
with the human papillomavirus (HPV) E6 protein originating from
the high-risk virus types 16 and 18 (Beaudenon and Huibregtse,
2008; Scheffner et al., 1993). The resulting E6AP and E6 complex
provides the specific E3 ligase activity in the transfer of polyUbs
onto p53 for the promotion of degradation, inhibiting p53-
dependent apoptosis pathways (Figure 2). Moreover, it has1564 Chemistry & Biology 18, 1562–1570, December 23, 2011 ª2011been discovered that E6AP ubiquitinates some endogenous
human proteins, such as HHR23A (a human homolog of the
yeast DNA repair protein Rad23) (Kumar et al., 1999) and PML
(promyelocytic leukemia) tumor suppressor (Louria-Hayon
et al., 2009), in an E6-independent manner, suggesting that it
also promotes the degradation of tumor-associated proteins.
Despite advances in understanding of the molecular mechanism
and structural study for HECT domains of E6AP (Huang et al.,
1999) and other related enzymes (Eletr and Kuhlman, 2007;
Ogunjimi et al., 2005), to the best of our knowledge, no selective
inhibitor against E6AP has been yet reported by means of high-
throughput screenings. Therefore, the development of inhibitors
against HECT domain remains a formidable challenge. We here
chose E6AP as a previously nondruggable target and performed
selection of anti-E6AP peptides using RaPID system.
E6AP HECT domain was expressed as a fusion protein with
an Avi-(His)6-tag followed by a solubility-enhancement tag GB1
(streptococcal B1 immunoglobulin-binding domain of protein
G) (Liu et al., 2009; Zhou et al., 2001) at the N terminus. This
protein construct, Avi-(His)6-GB1-HECT, in which Avi domain
was biotinylated during the expression, was immobilized on
streptavidin magnetic beads (SAvB, Figure 1B). The library was
applied to the protein beads, and the bound fractions were
selected at 4C in the first and second round (Figure 3A). From
the third round, GB1-immobilized SAvB was used as the nega-
tive selection to remove GB1-binding peptides, and then the
positive selection was performed at 37C to enrich the popula-
tion with specific binding activity against the HECT domain. In
the sixth round, we observed a significant increase in recovery
rate of active fractions (Figure 3A), and therefore the resulting
cDNA sequences in the pool were analyzed.
The sequence alignment of 47 clones revealed eight indepen-
dent sequence families found in the pool 6 (Figure 3B). Six fami-
lies, CM11-1–6, are originating from the (NNU)11 pool, whereas
the remaining two families, CM13-7 and CM13-8, are from the
(NNU)13 pool. The most abundant sequence, CM11-1, bearing
four N-methyl residues, shares several common signatures ofElsevier Ltd All rights reserved
Figure 3. In Vitro Selection of Macrocyclic N-Methyl-Peptides against E6AP HECT Domain and Selected Active Species
(A) Progress of the selection. Recovery rates of cDNA from each round were estimated by recovered amounts over input amounts of cDNAs monitored by
real-time PCR. The first and second rounds of selection were performed at 4C, and the subsequent rounds were performed at 37C. Those determined against
SAvB,biotin-Avi-(His)6-GB1-HECT as a positive selection are shown in blue, whereas those against SAvB,biotin-Avi-(His)6-GB1 as a negative selection shown
in red.
(B) Peptide sequences identified from the pool in round 6. The apparent frequency over a total number of clones andN-methyl amino acids of each sequence are
shown in parentheses and red, respectively. The parental random region is highlighted in gray, in which a dot denotes a residue that did not appear in the random
X12-15 region. Calculated (Calc.) and observed (Obs.) mass values ([M+H]
+) of each peptide expressed by FIT system are shown. See also Figure S1 and Table S1.
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MeF7, Y9,
MeF10, and
P11 are highly conserved in CM11-1–6 and CM13-7, where four
residues are notably the secondary amino acids. Among them,
MeF10/
MeG10 as well as
MeS4/
MeA4 substitutions were found
in CM11-2 and CM11-5/CM11-6, respectively, suggesting that
the role of side chain group may be less important in activity
but critical to be the N-methyl substituent. Moreover, MeG8
could be substituted with P8 observed in abundant CM11-3
and CM11-5, whereas another abundant CM11-4 and two other
independent peptides CM11-6–7 have R8 and S8, respectively.
This may suggest that X8 prefers to be the secondary amino
acid but tolerates other amino acid substitutions. Mutations
occurred during the course of selection is discussed more
details in the Supplemental Information (see Figure S1 available
online).
It is intriguing that the selection yielded only two lengths of
N-methyl-peptides from the (NNU)8–15 random region, given
that other lengths of peptides should coexist in the initial pool,
suggesting that the three-dimensional structure arisen from
these two lengths might be critical to exhibit binding activity
against E6AP HECT domain (Figure 3B). Importantly, the
successful outcomes clearly demonstrated that the N-methyl-
peptide library used in this study had a reliable quality and high
complexity giving the N-methyl residues in the random region,
and the RaPID system enabled us to select active species effec-
tively and rapidly. The observed similarity in the composition of
amino acid residues, particularly the positions as well as kinds
of N-methyl residues appeared in the sequences, also suggests
that specific interactions between the selected N-methyl-
peptides and E6AP HECT domain are very likely occurring.
Characterization of Isolated Anti-E6AP Macrocyclic
N-Methyl-Peptides
To confirmwhether the identifiedmRNA sequences of CM11-1–6
and CM13-7–8 correctly produced the encoding macrocyclic
N-methyl-peptides, we constructed the respective mRNA
templates with a substitution of UAG with UAA that acts as
a terminator of endogenous RF2 and performed in vitro expres-
sion using the same FIT system as the selection (Figure 3B, dataChemistry & Biology 18, 1562–157in the column of MALDI-TOF analysis). MALDI-TOF analysis of
the crude product expressed from the respective mRNA
template showed a clean peak of which molecular mass is
consistent with that calculated. This observation made us confi-
dent that the selected peptides had the N-methylated backbone
as well as the composition of residues, as we expected from the
cDNA sequences. For further characterization, we decided to
focus on three abundant peptides, CM11-1, CM11-3, and
CM11-5, all of which consist of a total of 14 amino acid residues.
The respective N-methyl-peptides were chemically synthesized
by standard Fmoc solid-phase chemistry where the C terminus
of G17 (corresponding to the 14th residue) was modified with
carboxyamide (Table S1).
Because the above three peptides have a cysteine residue
at position 1 (C1) in the random region adjacent to ClAc
DW, cycli-
zation between the ClAc group with C1 side chain designated by
UGU would potentially compete with that between the ClAc
group with C16 side chain designated by UGC. To decipher
which cyclization preferentially or selectively occurred, we
synthesized three peptides based on CM11-1 as a representative
peptide; one is CM11-1 itself, and the others are C1/S1 mutant
of CM11-1 (CM11-1S1) and the corresponding to linear N-methyl-
peptide by altering ClAc to acetyl (Ac) group, referred to as
LM11-1 (Table 1). Fragmentation of LM11-1 by MALDI-TOF/
TOF yielded peaks corresponding to linear fragments, as
expected (Figure S2A). On the other hand, MALDI-TOF/TOF
fragmentation of CM11-1 and CM11-1S1 was much difficult
than that for LM11-1, and both gave similar fragmentation
patterns (Figures S2B and S2C). Importantly, we were able to
identify peaks corresponding to fragments containing the thio-
ether linkage between the N-terminal acetyl group and the sulf-
hydryl group of C16 side chain in both CM11-1 and CM11-1S1, but
not between Ac and C1 side chain in CM11-1. These results well
agree with the selective formation of the thioether linkage of
Ac-S-C16.
To evaluate the binding abilities of chosen peptides, CM11-1,
CM11-3, and CM11-5 (a series of these peptides are referred to
as CM11-peptides), we determined their kinetic and dissociation
constants by means of surface plasmon resonance (SPR)0, December 23, 2011 ª2011 Elsevier Ltd All rights reserved 1565
Table 1. Kinetic and Equilibrium Constants of Macrocyclic N-Methyl-Peptides against E6AP HECT Domain
Datawere collected by the standard SPRmethod using Biocore T100 and the constants were generated by the equipped data fitting program. See also
Figures S2 and S3.
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bilized on a SAv-sensor chip (Table 1). All macrocyclic CM11-
peptides have values of kon with a range of 0.2–3 3 10
6
M1s1, koff with a range of 0.3–3 3 10
3 s1, resulting in the
dissociation constants (Kd) with subnanomolar to 1 nM range.
Thus, the representative CM11-peptides studied here have
remarkably strong affinity to E6AP HECT domain, and particu-
larly CM11-1 has the lowestKd values among the CM11-peptides.
In addition to the CM11-peptides, we synthesized the respective
linear peptides bearing N-terminal acetyl group, referred to as
LM11-peptides. All LM11-peptides lost affinity over 170-fold.
This suggests that the macrocyclic structure closed by the Ac-
S-C16 thioether bond in CM11-peptides is crucial to exhibit high
binding activity to the HECT domain.
In addition to the above peptides, we synthesized three more
mutants of CM11-1 to further validate the importance of the
specific structure. One was the aforementioned C1/S1 mutant
peptide, CM11-1S1, and the others are a macrocyclic peptide
without N-methyl backbone but having the same side chains,
CP11-1, and its linear peptide, LP11-1 (Table 1). CM11-1S1 had
a 9-fold faster koff rate than CM11-1, implying that C1 somehow
contributes to slowing the dissociation from the target site but
is not absolutely essential for binding activity. On the other
hand, the other two mutants completely lost binding ability,
indicating that N-methylated backbone with the N-terminal
Ac-C16 thioether macrocycle is crucial to maintain the full
binding capability of CM11-1 against E6AP HECT domain.
Furthermore, we verified the binding specificity of CM11-
peptides against E6AP HECT domain using a different HECT-1566 Chemistry & Biology 18, 1562–1570, December 23, 2011 ª2011type E3 Ub ligase, Smurf2 (Ogunjimi et al., 2005). None of
CM11-peptides had any SPR signature of binding against Smurf2
Avi-(His)6-GB1-HECT domain immobilized on a SAv-sensor
chip, indicating that CM11-peptides have high selectivity toward
the E6AP HECT domain over Smurf2 HECT domain nor
Avi-(His)6-GB1-tag region (data not shown). Moreover, we inves-
tigated human plasma stability of CM11-peptides compared with
other control peptides (see more details in Supplemental Infor-
mation and Figure S3), indicating that a CM11-peptide (CM11-
1S1) is very stable in plasma. Taken together, CM11-peptides
have remarkable binding activity and specificity to E6AP HECT
domain and plasma stability.
CM11-1 Inhibits Ubiquitination of Target Proteins
Catalyzed by E6AP
Despite the observation of strong binding activity of CM11-
peptides to E6AP HECT domain, it does not necessarily mean
that they are able to inhibit the E6AP ubiquitination activity. To
assess whether CM11-peptides have an ability to inhibit the
ubiquitination activity, we chose the most active CM11-1 and
performed an in vitro assay to monitor ubiquitin thioester forma-
tion. It is known that E6AP or even its HECT domain alone forms
the ubiquitin thioester intermediate (Beaudenon et al., 2005;
Scheffner et al., 1990; Scheffner et al., 1995) in the presence of
Ub, E1, and E2 in vitro (Figure 2). When an in vitro translation
system from rabbit reticulocyte lysate (RRL), which contains
these essential Ub-related components, was used for trans-
lating the E6AP HECT domain from the appropriate mRNA
template in the presence of [35S]-Met (Huibregtse et al., 1995),Elsevier Ltd All rights reserved
Figure 4. Inhibition of Ub-Thioester Formation with E6AP HECT
Domain and Polyubiqutination of Target Proteins by CM11-1 and Its
Derivatives
(A) Inhibition of Ub-thioester formation with E6AP HECT domain. 35S-labeled
E6AP HECT (43 kDa) was translated in a rabbit reticulocyte lysate cell-free
translation system. Because the translation lysate supposedly contained
ubiquitin (8 kDa), E1, and E2, the expressed E6AP HECT would be endoge-
nously converted to the ubiquitin-adduct (E6AP HECT-Ub, 51 kDa). The
translation mixture was treated with various concentrations of peptides
(103–10 mM) at room temperature for 30 min. The resulting mixtures were
analyzed by SDS-PAGE without DTT. xWhen the Ub-thioester formation on
E6AP was inhibited by CM11-1 (as well as 10 mM LM11-1), a slower migrating
band than Ub-E6AP appeared on the gel. Although the product of this band
has not yet been defined, this band disappeared upon addition of a free thiol
reagent such as DTT (data not shown), suggesting a possibility of dimer
formation of HECT domain via a disulfide bond. Alternatively, the free cysteine
in HECT domain formed a disulfide bond with other proteins containing a free
cysteine residue.
(B) Inhibition of E6-independent polyubiquitination on Prx1. (His)6-Prx1 was
incubated with 250 nM MEF-E6AP or inactive mutant MEF-E6APC843A, (His)6-
E1, (His)6-UbcH7, ubiquitin and peptide at 37
C for 30 min. Reaction products
were immunoprecipitated with anti-Prx1 pAb and visualized by antiubiquitin
mAb immunoblotting. Asterisk denotes immunoglobulin heavy chain. {As a
negative control, DMSO used as a cosolvent for CM11-1 inhibition was added.
(C) Inhibition of E6-dependent polyubiquitination on p53. p53 was incubated
with 170 nM MEF-E6AP, (His)6-E1, (His)6-UbcH7, ubiquitin, HPV16 E6, and
peptide at 37C for 30 min. Reaction products were immunoprecipitated with
anti-p53 pAb and visualized by antiubiquitin mAb immunoblotting. See also
Figure S4.
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Chemistry & Biology 18, 1562–157a Ub-thioester intermediate of the 35S-Met-labeled HECT
domain (Ub-HECT) was distinguished from the parental HECT
domain bymeans of a SDS-PAGEmobility shift assay (Figure 4A,
lane 1). When CM11-1 was added to this translation assay
system, the migration shift was suppressed at 1 mM or higher
concentrations (lanes 5 and 6). As a negative control, LM11-1
and CP11-1 were also tested for the same inhibition assay, in
which an approximately 50% inhibition was observed at 10 mM
LM11-1, whereas neither 1 mM LM11-1 nor 10 mM CP11-1
exhibited the inhibition. Although the observed potency by
CM11-1 seemed not as strong as expected from the SPR data,
this could be attributed to that the RRL translation system might
contain endogenous label-free E6AP (Huibregtse et al., 1991;
Scheffner et al., 1993) that might interact with some fractions
of CM11-1, resulting in a reduction of the apparent inhibitory
potency. Nevertheless, this result suggests that CM11-1 is able
to inhibit the charge of Ub onto the HECT domain of E6AP.
We then have further pursued testing inhibition of E6AP-
catalyzed polyubiquitination on target proteins. Peroxiredoxin 1
(Prx1) is an endogenous substrate of E6AP in human cells, and
its polyubiquitination occurs independently from the presence
of E6 (Nasu et al., 2010). To monitor the inhibitory action of
CM11-1 against E6AP, we used an in vitro-reconstituted Prx1
polyubiquitination assay system, in which purified His-tagged
Prx1 was incubated with E6AP tagged with MEF (Myc-TEV
protease site-flag) and ubiquitin in the presence of purified His-
tagged E1 and E2 (UbcH7). The resulting polyubiquitinated
Prx1 (Prx1-Ubn) and free Prx1 were immunoprecipitated by
anti-Prx1 polyclonal antibodies and were immunoblotted by an
anti-Ub monoclonal antibody to visualize in SDS-PAGE (Fig-
ure 4B, lanes 1–9). As negative controls, LM11-1 and CP11-1
were also included in this examination. Clearly, polyubiquiti-
nation of Prx1 was inhibited by CM11-1 in a dose-dependent
manner (lanes 5–9), where an approximately 1 mM of CM11-1
nearly shut down the E6AP activity. On the other hand, neither
LM11-1 (lanes 10 and 11) nor CP11-1 (data not shown) was
able to inhibit polyubiquitination. We also tested Prx1-poly-
ubiquitination inhibition by CM11-1S1, showing a weaker inhibi-
tory activity than CM11-1 (Figure S4); the result seemed con-
sistent with the Kd values for both peptides observed in SPR
experiments.
Finally, we examined the inhibitory activity of CM11-1 against
polyubiquitination on an E6-dependent substrate, p53, using
a reconstituted p53 polyubiquitination assay system. Immuno-
precipitation of poly- and nonubiquitinated p53 using anti-
p53 pAb followed by immunobolotting using anti-Ub mAb
enabled us to detect the polyUb-p53 on SDS-PAGE (Figure 4C).
Again, 1 mMCM11-1 was able to inhibit polyubiquitination of p53
in a dose-dependent manner (lanes 3–6), whereas the control
peptide, LM11-1, was not (lane 7). The result shows that CM11-
1 acts as an E6AP inhibitor that prevents polyubiquitination of
Prx1 and p53 in E6-independent and E6-dependent manner,
respectively. The trend of Kd values of CM11-1 and its mutant
peptides against E6AP HECT domain determined by the SPR
experiments well reflected to their observed inhibitory behaviors
against ubiquitination of target substrates (Table 1 and Figure 4).
Because the present assay method allowed us to detect poly-
ubiquitination instead of monoubiquitination of the substrate
proteins catalyzed by an excess amount of E6AP (greater than0, December 23, 2011 ª2011 Elsevier Ltd All rights reserved 1567
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the observed inhibitory potency of CM11-1 was only qualitatively
assessed. Most importantly, CM11-1 was capable of inhibiting
Ub ligase activity of E6AP even though it was simply selected
by binding to E6AP.
SIGNIFICANCE
Here, we have demonstrated RaPID selection of ‘‘natural
product-like’’ peptides consisting of thioether-macrocyclic
and N-methylated backbone. The selection against E6AP
HECT domain has yielded such desired peptides with
remarkable binding abilities, falling in a range of Kd values
from a subnanomolar to a single-digit nanomolar. One of
the representative peptides, CM11-1, chosen for further
studies has displayed inhibitory activity against E6AP-
catalyzing polyubiquitination on the target proteins, Prx1
and p53. The present work provides the proof-of-technology
of RaPID system that enables for the discovery of potent
inhibitors against a previously nondruggable ubiquitin
ligase, thus opening a wide range of possibilities in the
discovery of inhibitors against other ubiquitin ligase families.
Most importantly, the natural product-like macrocyclic
N-methyl-peptides have larger interaction surfaces com-
pared with small organic molecules, as well as elevated
stability under physiological conditions compared with
ordinary peptides; therefore, they would provide tremen-
dous potentials for the development of drug leads that
disrupt not only enzyme activities but also protein-protein
interactions.
EXPERIMENTAL PROCEDURES
In Vitro Translation and Selection
Translation of the first round selection was performed using 100 pmol mRNA-
puromycin (initial complexity is 63 1013) and 150 ml of translationmixture in the
presence of 3750 pmol of ClAcDW-tRNAfMetCAU,
MeG-tRNAAsn-E2GAU,
MeA-
tRNAAsn-E2GGC,
MeS-tRNAAsn-E2GAG, and
MeF-tRNAAsn-E2GAA (25 mM each), at
37C for 30 min. Subsequently, the translation mixture was incubated at
room temperature for 12 min to conjugate the translated peptide with the cor-
responding mRNA-puromycin. This solution was incubation with 15 ml of
200 mM EDTA (pH 8.0) at 37C for 30 min in order to dissociate ribosomes
from mRNA-peptide complexes. For the first-round selection, 11 ml of E6AP
HECT immobilized streptavidin magnetic beads (Dynabeads M-280, Invitro-
gen) was used at a concentration of 200 nM target protein, and mixed with
the solution of mRNA-displayed N-methyl-peptides. The binding reaction
was performed at 4C for 30minwith rotation. After supernatant was removed,
the bead was washed with 300 ml of cold wash buffer (100 mM Tris-HCl [pH
7.5], 300 mM NaCl, 0.05% [v/v] tween 20). To the bead was added 40 ml of
RT reaction buffer (50 mM Tris-HCl [pH 8.3], 75 mM KCl, 3 mM MgCl2,
10 mM DTT, 0.5 mM dNTPs, 2 mM CGS3an13.R39) containing 200 units of
M-MLV reverse transcriptase (Promega) and 8 units of RNase inhibitor (Prom-
ega), and reverse transcribed at 42C for 60 min with rotation. The selected
cDNA was eluted with 360 ml of PCR buffer (10 mM Tris-HCl [pH 7.5],
50 mM KCl, 0.1% [v/v] Triton X-100, 2.5 mM MgCl2, 0.25 mM dNTPs,
0.25 mM T7g10M.F48, 0.25 mM CGS3an13.R39) at 95C for 5 min. After addi-
tion of TaqDNA polymerase to the eluate, themixture was used for PCR ampli-
fication. The amplified DNA was purified by the extraction with phenol/chloro-
form and ethanol purification and was used for the next round of selection.
Since the second round, 10 ml scale of transcription and 7.5 ml of ligation
with puromycin linker were carried out. The resulting mRNA-puromycin of
the second round was translated using 5 ml of the translation mixture in the
presence of each 25 mMacyl-tRNAs at 37C for 30min, followed by incubation1568 Chemistry & Biology 18, 1562–1570, December 23, 2011 ª2011at room temperature for 12 min. After incubation with 1 ml of 100 mM EDTA
(pH 8.0) at 37C for 30 min, the reverse transcription of the mRNA-displayed
peptides was performed by RT reaction buffer in the presence of M-MLV
reverse transcriptase without RNase H activity (Promega), at 42C for 60 min
with rotation. After quenching the reaction with 1 ml of 100 mM EDTA (pH
8.0), the solution was neutralized with 1.1 ml of 0.2 M HCl. The complexes
with cDNA- and mRNA-displayed peptides were subjected to 2.4 ml of the
magnetic bead without target and were incubated at 4C for 30 min for nega-
tive selection at once. Subsequently, the supernatant was mixed with 0.8 ml of
the magnetic bead with E6AP HECT and was incubated with 4C for 30min for
positive selection, followed by thrice washing with 10 ml of cold wash buffer.
After addition of 100 ml of PCR buffer to the bead, the cDNA were eluted at
95C for 5 min and amplified by Taq DNA polymerase. In the third round and
all subsequent rounds, the all experiments were performed by a half of the
reaction scale of the second round. Moreover, negative selection was per-
formed at 4C for 20 min at three times in the third and fourth round, and at
nine times in the fifth and sixth round. On the other hand, positive selections
after second round were performed by mixing with the complexes of cDNA
and mRNA-displayed peptides and 200 nM E6AP HECT (not immobilized
on streptavidin magnetic bead) at 37C for 30 min, followed by pull down by
streptavidin magnetic bead at 37C for 5minwith rotation. After thrice washing
with 5 ml of wash buffer at room temperature, the selected cDNA was eluted
with 100 ml of PCR buffer at 95C for 5 min. After addition of Taq DNA poly-
merase to the eluate, the mixture was used for PCR amplification. To monitor
the convergence of the selection process, real-time PCR (RT-PCR) was used
to quantify the amounts of input and output DNA in every round. For input
cDNA, 0.25 ml aliquot of the RT mixture was diluted with 150 ml of a dilution
solution (10 mM Tris-HCl [pH 8.0] and 300 mM NaCl), and 1 ml of the diluted
cDNA was mixed with 19 ml of PCR buffer containing SYBR Green I (Molecular
Probe) and Taq DNA polymerase. For output cDNA, 1 ml aliquots of the eluates
from the beads of positive and negative selections were mixed with 10 ml of
PCR buffer containing SYBR Green I and Taq DNA polymerase. The reverse
transcribed (NNU)10 mRNA mixture was serial-diluted and used for the
templates as standards.
MALDI-TOF Analysis of Translated Clone Peptides
To identify the expressed cyclicN-methylated peptides, a 5 ml scale translation
reaction was performed using FIT system with 40 nM of clone DNA, 25 mM
each of ClAcDW-tRNAfMetCAU,
MeG-tRNAAsn-E2GAU,
MeA-tRNAAsn-E2GGC,
MeS-
tRNAAsn-E2GAG, and
MeF-tRNAAsn-E2GAA at 37
C for 30 min. After quenching
with 0.2% TFA, the crude peptide mixture was desalted with C-Tip (C18
desalting SPE, Nikkyo technos) and eluted with 80% acetonitrile and 0.5%
acetic acid solution saturated with the matrix a-cyano-4-hydroxycinnamic
acid (Bruker Daltonics). MALDI-TOF analysis was performed using an Autoflex
TOF/TOF (Bruker Daltonics) and peptide calibration standard II (Bruker Dalton-
ics) as external standards.
SPR Analysis of Peptides
The interaction between E6AP HECT and peptides was assessed using
a BIACORE T100 instrument (GE Healthcare) equipped with research-grade
streptavidin sensor chip at 25C. Biotinylated E6AP HECT was immobilized
to a surface density of approximate 1,500 response units (RU) using standard
immobilization protocols (GE Healthcare). HBS-EP+ (10 mM HEPES [pH 7.4],
150 mM NaCl, 3 mM EDTA, and 0.05% [v/v] surfactant P20) containing 1.0%
(v/v) DMSOwas used as the running buffer for all experiments. Peptide binding
was tested by injecting varying concentrations (0.3 nM to 1,000 nM) at a flow
rate of 30 ml min1 and measured by single cycle kinetics method. Raw data
were analyzed by the BIACORE T100 evaluation software 2.01 and fitted to
the standard 1:1 interaction model.
In Vitro Ubiquitin Transfer Assay by 35S-Labeled E6AP HECT
E6AP HECT cDNA was subcloned into pTNT vector (Promega) at XhoI and
SalI sites. 35S-Methionine-labeled E6AP HECT was synthesized in vitro by
TNT T7 coupled rabbit reticulocyte lysate system (Promega) at 30C for
90 min, by following the standard procedure (Huibregtse et al., 1995). After
translation, 0.5 ml of peptides in 10% (v/v) DMSO with 103 concentrations
shown in Figure 4A were added to the translation reaction mixture (4.5 mL).
The resulting mixture was incubated at room temperature at 30 min andElsevier Ltd All rights reserved
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Tris-HCl [pH 6.8], SDS 4%, glycerol 20%, 0.002% bromophenol blue) in the
absence of dithiothreitol. Samples were subjected to SDS-PAGE on a 10%
polyacrylamide gel.
In Vitro Polyubiquitination Assay for Prx1 and p53
The plasmid pGEM p53 was used for in vitro translation (Werness et al., 1990).
In vitro translation was performed using TNT T7 coupled rabbit reticulocyte
lysate system. Recombinant baculovirus for HPV16 E6 was produced using
the BaculoGold system (PharMingen) as described previously (Shirakura
et al., 2007). Hi5 cells (Invitrogen) were infected with the recombinant baculo-
virus to produce HPV16 E6 protein. HPV16 E6 Protein was partially purified by
anion-exchange chromatography as previously described (Huibregtse et al.,
1993). In vitro polyubiquitination assays for Prx1 were performed essentially
as described previously (Nasu et al., 2010). Hi5 cells were infected with re-
combinant baculoviruses AcMEF-E6AP and Ac MEF-E6APC843A to produce
MEF-E6AP and MEF-E6APC843A, respectively (Shirakura et al., 2007). MEF-
E6AP and MEF-E6APC843A were purified on anti-FLAG M2 agarose beads
(Sigma) according to the manufacturer’s instructions. Assays were done in
40 ml volumes containing 20 mM Tris (pH 7.6), 50 mM NaCl, 5 mM MgCl2,
100 mM DTT, 5 mM ATP, 250 nM MEF-E6AP or inactive mutant MEF-
E6APC843A, 62.5 nM (His)6-E1, 1.1 mM (His)6-UbcH7, 25 mM ubiquitin, 8 mM
(His)6-Prx1 and peptide, and incubation at 37
C for 30 min. Reactions were
performed at 37C for 30 min. The ubiquitination reaction was terminated
by freezing the samples with liquid nitrogen. To dissociate proteins, 1%
SDS was added to lysates, which were then heated at 90C for 15 min. The
samples were diluted 10-fold with a dissociation dilution buffer containing
1% NP-40, 0.5% deoxycholate, 120 mM NaCl, 50 mM HEPES, 1 mM
EDTA, and complete protease inhibitor cocktail (Roche). Samples were
immunoprecipitated with anti-Prx1 PAb and analysis by immunoblotting
with antiubiquitin mouse monoclonal antibody (anti-Ubi-1, Millipore) to detect
ubiquitinated Prx1. In vitro polyubiquitination assays for p53 were performed
essentially as described previously (Nakagawa and Huibregtse, 2000). Assays
were done in 75 ml volumes containing 25 mM Tris-HCl (pH 8.0), 125mMNaCl,
2 mM MgCl2, 50 mM DTT, 5 mM ubiquitin, 2 mM ATP, 170 nM MEF-E6AP,
33 nM (His)6-E1, 0.6 mM (His)6-UbcH7, 2 ml of partially purified HPV16 E6,
and 5 ml of in vitro translated p53. Peptides inhibitors were added to the
samples as indicated. The reaction mixtures were incubated at 37C for
30 min. The ubiquitination reaction was terminated by freezing the samples
with liquid nitrogen. To dissociate proteins, 1% SDS was added to lysates,
which were then heated and diluted as described above. Samples were immu-
noprecipitated with anti-p53 rabbit polyclonal antibody (FL393, Santa Cruz),
followed by immunoblotting with antiubiquitin mouse monoclonal antibody
(anti-Ubi-1, Millipore) to detect ubiquitinated p53.
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